> > Severe asthma and nasal polyposis: A manifesto for improving adherence and treatment pathways...

Severe asthma and nasal polyposis: A manifesto to improve adherence and treatment pathways.

Severe asthma and nasal polyposis: A manifesto to improve adherence and treatment pathways.

(Adnkronos) - Recognizing therapeutic adherence as a treatment outcome and not the patient's fault, developing a unified care plan for those living with severe asthma and chronic rhinosinusitis with nasal polyps, and measuring what truly matters to those living with the disease. These are some of the six commitments of...

(Adnkronos) – Recognizing therapeutic adherence as a treatment outcome and not the patient's fault, developing a unified pathway for those living with severe asthma and chronic rhinosinusitis with nasal polyps, and measuring what truly matters to those living with the disease. These are some of the six commitments of the "Time for Care" Manifesto, presented today in Rome, at the Ministry of Health's Cosimo Piccinno Auditorium, during the institutional conference "Therapeutic Innovation for Longevity and Healthy Aging – New Models of Adherence and Sustainability of the National Health Service in Chronic Respiratory Diseases," promoted by the Longevitas Foundation.

The document, a note states, which is open to patient associations, scientific societies, healthcare professionals, and institutions, starts from a simple fact: for many people, years pass between diagnosis and a truly controlled life.  

In Italy, it is estimated that approximately 300 people have severe asthma. Six out of ten people do not achieve disease control, and this percentage accounts for up to 80% of the total resources allocated to asthma.

Chronic rhinosinusitis affects approximately 11% of the European adult population: up to a third of these patients develop nasal polyps, and up to 40% continue to have uncontrolled symptoms despite treatment and surgery. The two conditions often share the same inflammatory mechanism and can coexist in the same individual, but they are still managed on separate tracks: two specialists, two schedules, the same medical history to be told over and over again. 

“When a respiratory disease is not controlled,” said Eleonora Selvi, president of the Longevitas Foundation, “the first cost is paid by the people in time: the time it takes to get a diagnosis, the time spent in the hospital, the workdays lost by patients and the family members who accompany them.

With this Manifesto, we call for adherence to be interpreted for what it is—an indicator of the quality of the treatment pathway—and for it to be incorporated into the PDTA and regional evaluation systems. Treating a chronic disease well today also means allowing people to age better tomorrow.  

 

"The institutions' commitment," stated Simona Loizzo, XII Social Affairs Commission, Chamber of Deputies, "is to promote the implementation of all these innovative long-acting drugs. These drugs, in addition to improving patient adherence to treatment, substantially improve their quality of life. Monthly, annual, or quarterly administration certainly has a significant impact on patients' quality of life and increases adherence to the clinical protocol, resulting in a higher rate of recovery. Today," she continued, "we must consider that, as the average lifespan of our patients increases, from an institutional perspective we must create a skeletal network to support aging patients through active aging, encouraging exercise, healthier lifestyles, and also improving the quality of the medications delivered to our elderly patients' beds. This is in addition to a series of medical devices that can assist them remotely throughout their disease journey, making treatment more accessible at home." 

"Talking about innovation is of fundamental importance," emphasized Gian Antonio Girelli, member of the XII Social Affairs Commission, Chamber of Deputies, "because the healthcare of the future must be based on prevention and innovation, and doing so comprehensively, involving the older population is even more so. Let's not forget that early diagnosis often means saving the quality of life for the elderly in their remaining years, because a worsening of a disease often means a cessation of activity. And innovation means being able to make early diagnoses, being able to make the best medications available, and using telemedicine for timely checks on treatments. Comprehensive care for the individual is a healthcare issue, it's a social issue, because let's never forget that often, older people don't always have a supportive family or social context, and therefore need support. From this perspective, an alliance with the third sector, the network of local administrators, is truly essential. In short, it's a challenge that truly concerns everyone, and one that's definitely worth addressing. Investing. Our future quality of life and the sustainability of the National Health Service will depend on this, because we must never forget that prevention, early diagnosis, and appropriate treatment mean savings in direct healthcare spending and indirect socioeconomic costs, which always arise when a health emergency arises.  

 

"Innovation," emphasized Maria Sofia Rosati, Medical Director of GSK Italy, "can fully express its value when it translates into a tangible improvement in people's treatment journeys. Therefore, alongside research into new therapeutic solutions, it is essential to continue working on the quality of care, adherence, and integration between the various stakeholders in the system. Dialogue between institutions, the scientific community, and patient associations is essential to jointly identify outstanding needs and develop increasingly effective and patient-focused solutions." 

The first panel addressed the economic and social impact of therapeutic innovation, adherence, and care delivery, with Francesco Saverio Mennini, Head of the Department of Planning, Medical Devices, Drugs, and Policies for the National Health Service (NHS) at the Ministry of Health, and Eugenio Di Brino, Altems Advisory – Università Cattolica del Sacro Cuore.  

The second panel, dedicated to the upper and lower airways, brought together pulmonologists, ENT specialists, allergists, and general practitioners: Nicola Scichilone (President-elect of SIP/IRS), Michele Barbara (President of SIOeChCF), Vincenzo Patella (Past President of SIAAIC), Raffaele Scala (President of AIPO), Lorenzo Cecchi (Past President of AAIITO), Rosanna Cantarini (National Board of SIMG), and Pierluigi Bartoletti (Deputy Secretary of FIMMG). The discussion focused on the need for integrated and formalized pathways between the various specialties, shared criteria for early identification of those who are not being monitored, and a structured connection between the Emergency Department and specialist centers after each exacerbation. The third panel focused on patient longevity and quality of life, with Eleonora Selvi, Deborah Diso, head of Institutional Projects for the National Patient Association 'Respiriamo Insieme' Aps, and Sandra Frateiacci, national vice president of FederAsma e Allergie Odv and president of Alama Aps.  

 

The Manifesto's six commitments: 1. Adherence is a treatment outcome, not the patient's fault: it must be recognized as a measurable outcome in the PDTA and regional evaluation systems, alongside consumption and spending indicators. 2. Equal and timely access to innovation, wherever you live: shorter delays between national authorization and actual availability in the regions, uniform eligibility criteria, and guaranteed access to visits, diagnoses, follow-ups, and specialist centers. 3. One person, one path: integrated pathways between pulmonology, ENT, allergology, immunology, and general medicine, with a recognized role for family doctors and community centers. 4. A simple therapy must be matched by a more robust approach: the time freed up by simplifying treatment plans must be reinvested in the care relationship and monitoring, including through telemedicine. 5. Measure what matters to those living with the disease: patient-reported outcomes (PROMs), patient experience of services (PREMs), and quality of life must be consistently incorporated into pathway evaluations and registries. 6. Adherence is built with words, rather than prescriptions: communication time must be recognized as care time, with trained professionals and patient associations involved in information materials and therapeutic education programs. 

The Manifesto concludes with an appeal to national and regional institutions: make therapeutic adherence an explicit objective of chronic respiratory disease policies and consider innovation that simplifies and improves treatment as an investment in people's health and the sustainability of the National Health Service, not as an additional cost. Alessio Nardini, Director General of the Directorate General for Healthy Lifestyles and Relationships with the Ecosystem, spoke on behalf of the Ministry of Health. Speakers at the meeting included Simona Loizzo (XII Social Affairs Committee, Chamber of Deputies), Gian Antonio Girelli (XII Social Affairs Committee, Chamber of Deputies), and Senator Elena Murelli (Tenth Committee on Social Affairs, Health, and Labor, Senate), via video link. 

News

webinfo@adnkronos.com (Web Info)

Continue on the app The news of your city, in real time.
Open in app App Store